- Home
- HCWB vs DRCT Comparison
HCWB vs DRCT Comparison
Compare HCWB & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- DRCT
- Stock Information
- Founded
- HCWB 2018
- DRCT 2018
- Country
- HCWB United States
- DRCT United States
- Employees
- HCWB N/A
- DRCT N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- HCWB Health Care
- DRCT Technology
- Exchange
- HCWB Nasdaq
- DRCT Nasdaq
- Market Cap
- HCWB 10.8M
- DRCT 16.7M
- IPO Year
- HCWB 2021
- DRCT 2022
- Fundamental
- Price
- HCWB $4.30
- DRCT $0.53
- Analyst Decision
- HCWB Strong Buy
- DRCT Strong Buy
- Analyst Count
- HCWB 1
- DRCT 1
- Target Price
- HCWB $35.00
- DRCT $6.00
- AVG Volume (30 Days)
- HCWB 116.1K
- DRCT 155.6K
- Earning Date
- HCWB 08-13-2025
- DRCT 05-06-2025
- Dividend Yield
- HCWB N/A
- DRCT N/A
- EPS Growth
- HCWB N/A
- DRCT N/A
- EPS
- HCWB N/A
- DRCT N/A
- Revenue
- HCWB $1,445,145.00
- DRCT $48,170,000.00
- Revenue This Year
- HCWB $178.36
- DRCT $50.71
- Revenue Next Year
- HCWB N/A
- DRCT $26.31
- P/E Ratio
- HCWB N/A
- DRCT N/A
- Revenue Growth
- HCWB N/A
- DRCT N/A
- 52 Week Low
- HCWB $3.55
- DRCT $0.44
- 52 Week High
- HCWB $100.80
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- HCWB 42.79
- DRCT 44.72
- Support Level
- HCWB $4.02
- DRCT $0.50
- Resistance Level
- HCWB $4.44
- DRCT $0.57
- Average True Range (ATR)
- HCWB 0.31
- DRCT 0.05
- MACD
- HCWB 0.08
- DRCT -0.00
- Stochastic Oscillator
- HCWB 31.85
- DRCT 24.59
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.